系统性补体激活动态风险与进展为晚期年龄相关性黄斑变性的时间
这项队列研究纳入325例中间型年龄相关性黄斑变性(iAMD)患者,在2014至2022年间随访(平均3.9年),采用联合模型分析纵向测量的系统性补体因子及比值与进展至晚期AMD(地图样萎缩[GA]或新生血管性AMD[NVAMD])时间的关联。结果显示C4、C4b、C3a/C3、C5a/C5、sC5b-9/C5及因子I较高水平与进展至任何晚期AMD时间较短相关,C3a/C3和C5a/C5与GA风险相关。作者认为补体通路持续失调似乎增加iAMD进展风险。
要点
- C4b较高水平与进展至任何晚期AMD时间较短相关(HR 60.4,95%CrI 6.5-544)。
- sC5b-9/C5较高水平与进展至任何晚期AMD时间较短相关(HR 297,95%CrI 10-14877)。
- C3a/C3和C5a/C5较高水平与GA风险相关(HR分别为9.5和28.6)。
核心结论
- 补体通路持续失调似乎增加iAMD进展风险。
- 这支持识别iAMD高危患者以进行个性化眼科诊疗和靶向治疗以减轻iAMD进展风险的可能性。
研究设计与样本
- 在科罗拉多州奥罗拉Sue Anschutz Rodgers眼科中心开展的队列研究,2014至2022年进行。
- 纳入325例iAMD患者,随访至少1个月;数据分析于2024年9月至12月进行。
- 采用联合模型估计暴露与结局的关系,以风险比(HR)作为关联指标。
主要发现
- 325例参与者平均(SD)年龄76(7.0)岁,女性212例(65%),男性113例(35%)。
- 8年随访期间(平均3.9年),110例(34%)进展至任何晚期AMD,其中64例(20%)进展至GA,46例(14%)进展至NVAMD。
- C4较高水平与进展至任何晚期AMD时间较短相关(HR 6.8,95%CrI 1.7-26.2,P=.03)。
- C4b(HR 60.4,95%CrI 6.5-544,P<.001)、C3a/C3(HR 49.4,95%CrI 5.2-675,P<.001)、C5a/C5(HR 29.3,95%CrI 4.8-258,P<.001)、sC5b-9/C5(HR 297,95%CrI 10-14877,P=.003)及因子I(HR 525.9,95%CrI 5.5-107589,P=.02)较高水平与进展至任何晚期AMD时间较短相关。
- C3a/C3(HR 9.5,95%CrI 1.9-55.9,P=.01)和C5a/C5(HR 28.6,95%CrI 5.7-157.9,P<.001)较高水平与GA风险相关。
临床怎么用
- 作者认为补体通路持续失调似乎增加iAMD进展风险,这支持识别iAMD高危患者以进行个性化眼科诊疗和靶向治疗以减轻iAMD进展风险的可能性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Understanding the relationship between longitudinally measured systemic complement factors and intermediate AMD (iAMD) progression may enable the introduction of systemic therapeutics earlier in the disease course, before vision loss occurs. OBJECTIVE: To determine the contribution of longitudinal measures of systemic complement factors and ratios to time to progression to advanced AMD (geographic atrophy [GA] or neovascular AMD [NVAMD]). DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted at Sue Anschutz Rodgers Eye Center, Aurora, Colorado, from 2014 to 2022. Participants were patients with iAMD and at least 1 month of follow-up. Data analysis was performed from September to December 2024. EXPOSURES: Complement factors. MAIN OUTCOMES AND MEASURES: Time to progression to advanced AMD, either GA or NVAMD. Joint models were used to estimate the relationship between the exposures and the outcomes. The hazard ratio (HR) was a measure of association. RESULTS: Among 325 participants, the mean (SD) age was 76 (7.0) years; 212 participants (65%) were female and 113 (35%) male. During the 8-year follow-up period (mean, 3.9 years), 110 participants (34%) progressed to any advanced AMD. Sixty-four participants (20%) progressed to GA and 46 (14%) to NVAMD. Higher systemic levels of C4 (HR, 6.8; 95% credible interval [CrI], 1.7-26.2; P = .03), C4b (HR, 60.4; 95% CrI, 6.5-544; P < .001), C3a/C3 (HR, 49.4; 95% CrI, 5.2-675; P < .001), C5a/C5 (HR, 29.3; 95% CrI, 4.8-258; P < .001), sC5b-9/C5 (HR, 297; 95% CrI, 10-14 877; P = .003), and factor I (HR, 525.9; 95% CrI, 5.5-107 589; P = .02) were associated with shorter time to progression to any AMD. Levels of C3a/C3 (HR, 9.5; 95% CrI, 1.9-55.9; P = .01) and C5a/C5 (HR, 28.6; 95% CrI, 5.7-157.9; P < .001) were associated with the hazard of GA. CONCLUSIONS AND RELEVANCE: Continued dysregulation of complement pathways appears to increase the hazard of iAMD progression. This supports the possibility of identifying a high-risk group of patients with iAMD for personalized ophthalmic care and targeted treatments to attenuate the risk of iAMD progression.
引用
- Lynch AM, Grove NC, Wagner BD, et al. Dynamic Risk of Systemic Complement Activation With Time to Progression to Advanced Age-Related Macular Degeneration. JAMA Ophthalmol. 2025. PMID: 40504540. doi:10.1001/jamaophthalmol.2025.1608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。